Compare Baxter International Inc (BAX) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs L3Harris Technologies Inc — how do they compare? Baxter International Inc trades at $21.97 (market cap $11.26B), while L3Harris Technologies Inc trades at $290.65 (market cap $54.03B). The key difference: L3Harris Technologies Inc is far larger — about 4.8× Baxter International Inc's market cap, and L3Harris Technologies Inc pays the higher dividend (1.72%). Which is the better fit depends on your goals.
| BAX | LHX | |
|---|---|---|
Market Cap | $11.26B | $54.03B |
Sector | Health | Industrials |
52-Week High | $29.22 | $378.48 |
52-Week Low | $15.80 | $261.17 |
Enterprise Value | $18.93B | $64.79B |
Dividend Yield | 0.92% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
LHX trades at $288.69, down 0.72% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $2.72, beating estimates of $2.53, continuing a trend of earnings beats. Revenue grew to $21.87 billion in 2025, with net income margin improving to 7.34%. Recent contract wins include a U.S. Space Force satellite deal and U.S. Army communications orders, supporting growth prospects.
The outlook remains positive with a consensus price target of $367.50, implying 27% upside, and 75% of analysts rate it a Buy. Risks include execution on record $40.7 billion backlog, debt levels, and defense budget volatility. The stock offers dividend income with a $1.25 quarterly payout, balancing growth and income appeal for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
